Tag Archives: Private Credit

KKR Provides $600 Million Financing to Indian Conglomerate Manipal Group

KKR

Transaction marks KKR’s latest and largest credit investment in India

MUMBAI, India–(BUSINESS WIRE)– KKR, a leading global investment firm, and Manipal Education and Medical Group (“MEMG” or “Manipal Group”), a major diversified conglomerate in India, today announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601919977/en/

The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospitals chains in India.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”

Dr. Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”

Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

KKR is making its investment from its Asia Pacific Credit strategy and insurance platform. Since 2019, KKR has committed more than $8 billion across around 60 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than $21 billion.

Additional details of the transaction are not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Manipal Education and Medical Group (MEMG)

Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has evolved into a diversified conglomerate, with a strong presence in healthcare, education and health insurance in India and globally. MEMG’s operations touch the lives of over 20 million people annually with Manipal Hospitals scaling up to become the largest tertiary network in India. MEMG’s flagship University, Manipal Academy of Higher Education has been recognized as an Institute of Eminence by the Government of India. Claypond Capital, the family office of Dr. Pai and the investing arm of MEMG has been one of the more prolific investing family offices in India in the last 18 months. Their marquee investments include Aakash, BPL Medical, BlueStone, Easy Home Finance, First Cry, Finnable, InCred Finance, NSE, Panacea Medical, PharmEasy, Purpple, Recykal, SSI Innovations and Zepto.

Media Contacts

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Manipal Group
Shyam Powar
+91 98804 75000
Shyam.Powar@claypondcapital.com

Source: KKR

 

Download PDF

Categories: News

Tags:

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Blackstone

Previous term loan facility retired

NEW YORK – May 13, 2025 – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (“Blackstone”). Concurrent with this new facility, Axsome has retired its previous term loan with Hercules Capital. The improved financial terms and expected use of the new facility are expected to result in a significant reduction in interest expense.

“The new agreement with Blackstone simultaneously expands our total available credit facility by more than $200 million, and significantly reduces our cost of capital,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. “We are pleased to partner with the Blackstone team given their differentiated expertise in the life sciences industry. The improved terms of the new facility underscore our commitment to accelerating time to profitability and enhancing shareholder value, while advancing our mission to improve the lives of patients living with serious CNS disorders.”

“Blackstone is proud to partner with Axsome at a time of growth and expanding commercial opportunity,” said Craig Shepherd and Kiran Reddy, MD, Senior Managing Directors with Blackstone Life Sciences. “This investment is designed to reinforce the company’s operational and financial agility to support its next phase of growth, and it is a testament to Blackstone’s ability to deliver customized and flexible financing solutions to help leading biopharma companies achieve their strategic objectives.”

Brad Colman, Global Head of Healthcare with Blackstone Credit & Insurance, added, “Axsome’s proven commercial success, innovative pipeline, and strong leadership team make it an ideal partner as we continue to invest in transformative therapies to help patients. This transaction exemplifies how we can provide scaled credit solutions to world-class life sciences companies.”

The new $570 million facility consists of a $500 million term loan facility and a $70 million revolving credit facility. Upon closing of the agreement, the Company drew down a total of $120 million from the term loan facility which was used to retire the previous term loan with Hercules Capital. Under the terms of the new term loan facility, an additional $250 million may be drawn at the Company’s option, with an additional $200 million available subject to the approval of Blackstone. The facility bears interest at a calculated SOFR variable rate plus 4.75% for the term loan, and SOFR variable rate plus 4.0% for the revolving credit facility. The facility matures in May 2030 and has an interest-only payment period of 60 months. Concurrent with the closing of the agreement, Blackstone purchased $15 million of Axsome common stock at the 30-day volume weighted average price per share equal to $107.14.

Additional details regarding the financing agreement are available in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.

About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $12 billion in assets under management.

About Blackstone Credit & Insurance
Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset-based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Axsome Contacts:

Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com

Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

Blackstone:
David Vitek
(212) 583-5291
David.Vitek@blackstone.com

Categories: News

Tags:

Blackstone Launches BMACX – Blackstone Private Multi-Asset Credit and Income Fund

Blackstone

NEW YORK – May 1, 2025 – Blackstone (NYSE: BX) today announced the launch of Blackstone Private Multi-Asset Credit and Income Fund (BMACX), the firm’s first private multi-asset credit interval fund (the “Fund”). Investors can now access BMACX through select registered investment advisers.

BMACX aims to provide individual investors with a one-stop, private multi-asset credit solution designed to access strategies across Blackstone’s leading $465 billion credit platform. The Fund offers ticker execution with daily subscriptions, quarterly liquidity, and low investment minimums with capital invested immediately.

“We believe BMACX can be a powerful core portfolio building block to tap the expanding credit markets,” said Heather von Zuben, Chief Executive Officer of BMACX. “It brings the full breadth of Blackstone’s credit platform to individuals in what we see as an investor friendly structure.”

“We will aim to deliver high quality, diversified income with lower volatility than traditional fixed income products by investing across a diverse range of compelling credit assets,” said Dan Oneglia, Chief Investment Officer of BMACX. “We believe this multi-strategy approach positions investors to take advantage of attractive relative value, particularly in dynamic market environments.”

BMACX will invest across a diverse range of credit assets, including private corporate credit, asset based and real estate credit, structured credit, and liquid credit, seeking to deliver attractive and stable income through a monthly distribution while managing risk.

BMACX builds on Blackstone’s leadership position delivering private credit solutions to individual investors, with dedicated vehicles focused on direct lending available since 2018.

Blackstone announced that BMACX was declared effective by the U.S. Securities and Exchange Commission in March. More information is available at www.bmacx.com.

About Blackstone Credit & Insurance
Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

About Blackstone Private Wealth   
Blackstone Private Wealth was established to answer the growing demand for Blackstone products from high-net worth investors. Partnering with many of the world’s largest private banks and wealth management firms as well as family offices, Blackstone’s Private Wealth team packages and delivers the full breadth of Blackstone’s alternative product capability to these firms and their clients and provides ongoing product and advisor support, as well as education and training around alternatives.

Forward-Looking Statements
Certain information contained in this communication constitutes “forward looking statements” within the meaning of the federal securities laws. These forward-looking statements can be identified by the use of forward-looking terminology, such as “outlook,” “indicator,” “believes,” “expects,” “potential,“ “continues,” “may,” “can,” “will,“ “could,” “should,” “seeks,” “approximately,” “predicts,“ “intends,” “plans,” “estimates,” “anticipates”, “confident,” “conviction,“ “identified” or the negative versions of these words or other comparable words thereof.

These may include financial estimates and their underlying assumptions, statements about plans, objectives and expectations with respect to future operations, statements regarding future performance, statements regarding economic and market trends and statements regarding identified but not yet closed investments. Such forward-looking statements are inherently subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in such statements. BMACX believes these factors also include but are not limited to those described under the section entitled “Risk Factors” in its prospectus, and any such updated factors included in its periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this document (or BMACX’s prospectus and other filings). Except as otherwise required by federal securities laws, BMACX undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This press release must be read in conjunction with the BMACX prospectus in order to fully understand all the implications and risks of an investment in BMACX. This press release is neither an offer to sell nor a solicitation of an offer to buy securities. An offering is made only by the prospectus, which should be read carefully before investing and is available at www.bmacx.com.  Before investing you should carefully consider BMACX’s investment objectives, risks, charges and expenses.  This and other information is in BMACX’s prospectus.

An investment in the Fund involves a high degree of risk. There is no assurance that the Fund will achieve its investment objectives.  An investment in the Fund is suitable only for investors who can bear the risks associated with limited liquidity.  Shares of the Fund are not listed on any securities exchange and the Fund does not expect any secondary market will develop for the shares. The Fund intends to utilize leverage and may utilize leverage to the maximum extent permitted by law for investment and other general corporate purposes, which will magnify the potential for loss on amounts invested in the Fund. Please see the prospectus for details of these and other risks.

The Fund is distributed by Blackstone Securities Partners L.P. BMACX is a newly formed investment company with no operating or performance history that shareholders can use to evaluate the Fund.

Contact
Thomas Clements
Thomas.Clements@blackstone.com
(646) 482-6088

Categories: News

Tags:

CVC Credit prices $475m Apidos LIII

CVC Capital Partners

CVC Credit, the $47bn global credit management business of CVC, is pleased to announce that it has successfully priced Apidos LIII (53), a new $475m Collateralized Loan Obligation (“CLO”). Societe Generale served as lead arranger for CVC Credit’s second US CLO New Issue pricing in 2025.

This is the third new CLO priced globally by CVC Credit in 2025, which combined have an aggregate value of c.$1.4bn (c.€1.3bn). Apidos LIII has a five-year reinvestment period and two-year non-call period, backed by a diversified portfolio of senior secured assets.

Cary Ho, Partner and Global Head of CLO origination at CVC Credit, said: “Apidos LIII was very well received from our global investors during very challenging market conditions, which reflects CVC’s proven track record, and the strength of our relationships with global investors across the capital stack.  We are happy with the structure and the quality of assets we have been able to purchase during the early stages of this deal.”

Quotes

We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalize on these opportunities.

Kevin O’MearaPartner and Global Co-Head of Performing Credit at CVC Credit

Kevin O’Meara, Partner and Global Co-Head of Performing Credit at CVC Credit, added: “Our team’s activity has remained robust over the past four months, even against the backdrop of increased volatility across financial markets. Since the inception of our business in 2005, our growing and loyal investor base has entrusted us with delivering stable and consistent performance throughout cycles.  We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalize on these opportunities.”

Categories: News

Tags:

Carlyle provides financing package to Suntera Global

Carlyle

St. Helier, Jersey, 22 April 2025 – Global investment firm Carlyle (NASDAQ: CG) today announced that its Global Credit platform has provided a financing package to Suntera Global (“Suntera”), an independent global provider of bespoke fund, corporate and private wealth services.

Founded in 1980, Suntera provides a full suite of professional services to corporates, fund managers, and private clients (including their family offices). Through a comprehensive range of administration, accounting and governance services, Suntera helps its long-standing international base of clients navigate the complex and evolving demands that come with managing wealth and cross-border capital, focusing on reducing clients’ compliance, regulatory, and reporting risks. The company employs more than 500 specialists in offices across Europe, Asia and North America.

This financing package will strengthen the company’s financial foundation by refinancing its existing indebtedness and provide additional capital to support Suntera through organic growth initiatives and strategic acquisitions.

Nicola Falcinelli, Deputy Head of European Private Credit at Carlyle, said: “We are delighted to support Suntera’s continued growth story through this strategic financing. We believe Suntera is strongly positioned to meet growing and resilient demand for specialized professional services, particularly within the context of a rapidly evolving and complex regulatory landscape. This transaction underscores Carlyle’s established strategy of supporting high-quality businesses with flexible capital solutions.”

David Hudson, CEO of Suntera, said: “Since the Management Buy Out in 2019, Suntera has built on its core heritage, grown its international footprint through strong organic and inorganic growth, and established a reputation for its highly specialized capability and diversified proposition which spans multiple strategies, geographies and service lines. We are grateful for the support of Carlyle, which enables Suntera to continue to pursue its growth ambitions through its first-class customer offering, and the continuation of its highly successful consolidation strategy.”

Carlyle’s Global Credit platform manages $192 billion in assets under management, as of December 31, 2024. It regularly pursues investments in privately negotiated capital solutions partnering with high-quality sponsors and leading family or entrepreneur-owned companies. The Suntera transaction follows an active last few months for Carlyle’s European credit platform, recently announcing investments including Argon, Sanoptis, and Bianalisi.

 

—

About Carlyle 

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $441 billion of assets under management as of December 31, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

About Suntera Global

Suntera Global is a multi-jurisdictional provider of fund, corporate and private wealth services. We believe in empowering responsible ambition through the professional delivery of fund, company and trust administration as well as outsourced compliance, accounting and tax services. Suntera employs over 500 specialists supporting a global client base from offices in the Bahamas, the Cayman Islands, Hong Kong, the Isle of Man, Jersey, Guernsey, Luxembourg, the UK and the USA.

For more information visit suntera.com

 

Media contacts:

Carlyle:

Charlie Bristow

Tel: +44 (0) 7384 513568

Email: charlie.bristow@carlyle.com

 

Suntera Global: 

Cara Pyper
cara.pyper@suntera.com

Categories: News

Tags:

Coller Capital partners with Barings Portfolio Finance and Ares on $2.4 billion structured funding vehicle to invest in private market secondaries

Coller Capital

London, April 17, 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, today announces that it has partnered with Barings Portfolio Finance and Ares Management Alternative Credit funds (“Ares”) to raise a $2.4 billion structured funding vehicle for Coller funds to invest in private market secondaries.

This innovative solution marks the largest-ever structured funding vehicle of its kind in the secondary market to invest in both private equity and private credit secondaries. This transaction was led by Coller’s Structured Solutions team and builds on the firm’s track record of capital raising through innovative structured solutions, the fifth such issuance since 2020.

Barings Portfolio Finance acted as the Lead lender for the transaction with Coller Capital and Ares providing the credit enhancement. Citi acted as agent on the transaction. KBRA provided a rating for the debt. Debevoise and Plimpton LLP served as legal counsel for Coller. Proskauer Rose LLP served as legal counsel for Ares. Cadwalader, Wickersham & Taft LLP served as counsel for Barings and Citi.

Remy Kawkabani, Deputy Managing Partner and Head of Capital Formation, Coller Capital, commented: “We are delighted to partner with Barings and Ares on this bespoke structured solution to invest in private market secondaries. Coller brings a 35-year track record of innovative firsts in private markets and we are pleased to lead on the largest-ever structured funding vehicle of its kind for private market secondaries.”

Ian Wiese, Managing Director, Barings Portfolio Finance, commented: “Coller and Barings have a long-standing relationship, and we are pleased to partner to develop an attractive investment grade solution that appeals to institutional investors. As this market continues to innovate, we believe, together with Coller, we will remain at the forefront of creating solutions and look forward to what lies ahead.”

Richard Sehayek, Managing Director, Co-Head of Europe for Ares Alternative Credit, commented: “We are excited to be able to support the Coller team during this dynamic period in global markets. This transaction underscores Ares’ ability to deliver creative, flexible capital solutions that provide important liquidity to market participants, and we look forward to the growing opportunities ahead.”

Mentions
Remy Kawkabani

Deputy Managing Partner and Head of Capital Formation
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

Categories: News

Tags:

Coller Capital Acquires $1.6bn Senior Direct Lending Portfolio in Landmark LP-led Credit Secondaries Transaction

Coller Capital

London, April 2 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, has acquired a $1.6bn senior direct lending portfolio from American National, a multiline US insurer. The investment marks the largest ever LP-led credit secondaries transaction that is focused on a senior direct lending portfolio.

The transaction will see Coller Capital acquire LP positions in 44 US credit funds that are primarily focused on senior direct lending. The portfolio focuses on first lien and unitranche loans to mid-market companies and, at acquisition, was diversified across over 3,000 loans and nearly 1,500 borrowers, the majority US based.

Coller Capital was approved to buy all funds by the underlying GPs, reflecting the firm’s widely recognised scale, expertise and experience when it comes to structuring and executing LP-led secondaries credit transactions.

Michael Schad, Partner, Head of Coller Credit Secondaries, said: “This investment marks the largest of its kind to date. It is a classic Coller Capital transaction in that it required scale, innovation and specialist expertise to solve a complex challenge. Ultimately, it underlines our pioneering position in the credit secondary space.

“While interest in private credit secondaries continues to grow, the market remains undercapitalized relative to deal volumes. We believe that as more capital becomes available to address this imbalance we will see an increase in transactions of this size.”

Martins Marnauza, Partner at Coller Capital said: “This is a landmark transaction demonstrating the benefits of our global scale and capabilities in the secondary market, as well as the benefits of a seasoned team. The investment highlights our ability to effectively structure and swiftly execute on transactions and helps us continue to provide our investors with exposure to a diversified portfolio of high-quality assets.”

Jefferies LLC acted as adviser to American National, with Debevoise and Plimpton LLP serving as legal counsel. Akin Gump Strauss Hauer & Feld LLP and Simpson Thacher & Bartlett LLP served as legal counsel for Coller Capital.

In 2024, Coller Capital announced the closing of a GP-led transaction to create a continuation vehicle for Abry Advanced Securities Fund III (“ASF III” or the “Fund”). The GP-led transaction represented the largest credit continuation vehicle ever created with $1.6 billion of assets.

Mentions
Black and white formal headshot of Michael Schad.
Michael Schad

Partner, Head of Coller Credit Secondaries
Black and white formal headshot of Martins Marnauza.
Martins Marnauza

Partner, Investment
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

Categories: News

Tags:

Carlyle provides €250 million strategic capital for Sanoptis

Carlyle

Zug, Switzerland and London, UK, 25 March 2025 – Global investment firm Carlyle (NASDAQ: CG) today announced that its Global Credit platform has provided a strategic investment of EUR 250 million to Sanoptis, a European leader in ophthalmology services. The investment, which is through a preferred equity instrument, will be used to accelerate Sanoptis’ growth, including the continued expansion of Sanoptis’ European footprint through M&A and investment in state-of-the-art technologies and treatments.

Majority-owned by investment company Groupe Bruxelles Lambert (“GBL”) (ENXTBR: GBLB), Sanoptis is one of Europe’s largest ophthalmology services providers with over 450 locations across Germany, Switzerland, Italy, Spain, Austria and Greece. With c.4,700 employees, the company performs 3.3 million treatments per year in conservative ophthalmology consultations as well as in surgeries, while adhering to the highest standards of quality in healthcare.

Adnan Khalef, a Managing Director in Carlyle’s European Private Credit business, said: “We are delighted to provide this strategic investment to Sanoptis in order to strengthen and expand their leading position in ophthalmology services in Europe. We are also pleased to partner with GBL, a leading investor in Europe, who is focused on long-term value creation and benefits from a supportive family shareholder base. The transaction demonstrates our ability to provide flexible capital solutions to strong European businesses to accelerate their growth trajectory.”

Volker Wendel, CEO and Founder of Sanoptis, said: “We are very excited that Carlyle is joining us as a new partner alongside our lead investor GBL. This capital increase is, above all, excellent news for our network. It underscores our commitment to our mission of making high-quality ophthalmology accessible to everyone.”

Michal Chalaczkiewicz, Investment Partner at GBL, said: “We are thrilled about this partnership with Carlyle and our ability to further accelerate the growth trajectory of Sanoptis. Carlyle’s track record and confidence in this endeavour further attests to the value-creation potential this platform holds and represents another important proof point of GBL’s private assets’ strategy.”

Carlyle’s Global Credit platform manages $192 billion in assets under management, as of December 31, 2024. It regularly pursues investments in privately negotiated capital solutions partnering with high-quality sponsors and leading family or entrepreneur-owned companies. The Sanoptis transaction follows the final close of the third Carlyle Credit Opportunities Fund (“CCOF III”) in December 2024, which raised $7.1 billion in investable capital.

Jefferies acted as sole financial adviser to Sanoptis and GBL on this transaction.

—

About Sanoptis

Sanoptis is a leading provider of ophthalmology services in Europe, operating a network of over 450 locations across Germany, Switzerland, Italy, Spain, Austria, and Greece. With a team of c.4,700 professionals, Sanoptis delivers high-quality eye care through state-of-the-art clinics and ophthalmic practices, performing approximately 3.3 million treatments annually, including both conservative consultations and surgical procedures. Committed to medical excellence, innovation, and patient-centric care, Sanoptis partners with leading ophthalmologists to ensure the highest standards in diagnostics and treatment. The company provides access to modern infrastructure, advanced technologies, and sustainable growth opportunities while preserving the entrepreneurial independence of its affiliated clinics and practices. For more information, visit www.sanoptis.com.

 

About Carlyle 

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $441 billion of assets under management as of December 31, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

About Groupe Bruxelles Lambert (“GBL”) 

Groupe Bruxelles Lambert (“GBL”) is an established investment holding company, with seventy years of stock exchange listing and a net asset value of €15.7 billion at the end of December 2024. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base.

GBL aims to grow its diversified high-quality portfolio of listed, direct private and indirect private investments.

GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks.

GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is included in the BEL20 index.

 

Media Contacts

Sanoptis

Martin Cordes

Martin.cordes@sanoptis.com

+49 174 2319 621

 

Carlyle

Andrew Kenny

Andrew.kenny@carlyle.com

+44 7816 176120

Categories: News

Tags:

Carlyle and Arcmont provide €470 million financing package to Bianalisi

Carlyle

Milan, Italy, 28 February 2025 – The Global Credit platform of Carlyle (NASDAQ: CG) and Arcmont Asset Management, a leading European private credit asset management firm, today announced that they have arranged – together with Natixis – a €470 million financing package for Bianalisi, a leading independent platform for integrated healthcare diagnostics in Italy. The transaction will enable Bianalisi to continue supporting the ongoing expansion of its platform by investing in the consolidation of the Italian healthcare diagnostics market as well as to refinance existing debt. 

With a widespread presence in 13 Italian regions, Bianalisi offers a full range of services in clinical laboratory diagnostics, outpatient care and diagnostic imaging through a network of 350 labs and sample collection points, more than 70 outpatient care facilities, and 46 diagnostic imaging centers. Bianalisi has enjoyed significant growth over its 30-year history, both organic and through M&A, thanks to the efforts of its experienced management team, who today is led by CEO Giovanni Gianolli. Since receiving investment from Charme Capital Partners – an Italian private equity firm investing in Italy, UK and Spain – in 2021, Bianalisi has enjoyed an acceleration of its growth journey, with over 60 acquisitions completed since then.

Giovanni Gianolli, CEO of Bianalisi, said: “Thanks to this transaction, Bianalisi has secured substantial financial resources to continue its growth journey. We are delighted to partner with global investors such as Carlyle, Arcmont and Natixis who have chosen to support the continued consolidation project of Bianalisi in a highly promising sector. Their expertise and capital will help us further capitalize on the fragmented Italian healthcare market as we look to grow upon our strong market position.” 

Nicola Falcinelli, Deputy Head of European Private Credit at Carlyle, said: “We are pleased to support Bianalisi to further expand its delivery of critical healthcare services to Italian patients and healthcare professionals. The Italian market is one Carlyle knows well and we have been very active providing flexible credit solutions to both sponsor-backed and non-sponsored companies to further their growth.” 

Vanni Mario Zanchi, Partner at Arcmont, said: “We are pleased to provide this significant backing for Bianalisi, one of Italy’s leading medical diagnostics businesses. It meets many of the criteria we look for in an investment, including financial strength and stability and significant scope for continued growth. We look forward to working closely with Giovanni and his team in achieving their business goals while serving the needs of thousands of patients every day.” 

 

 

About Bianalisi

Bianalisi is a leading independent integrated diagnostics platform in Italy, offering healthcare services in laboratory diagnostics, outpatient diagnostics, and imaging diagnostics. With a widespread presence across 13 Italian regions, Bianalisi serves over 15,000 patients daily. Each year, the Group performs more than 1.5 million outpatient and imaging diagnostic visits and conducts approximately 20 million clinical tests, thanks to the work of over 1,500 doctors and 1,000 employees.

 

 

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $441 billion of assets under management as of December 31, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents.

Carlyle’s Global Credit platform manages $192 billion in assets under management, as of December 31, 2024. It regularly pursues investments in privately negotiated capital solutions partnering with high-quality sponsors and leading family or entrepreneur-owned companies.

Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

 

About Arcmont

Arcmont Asset Management, an investment affiliate of Nuveen, the investment manager of TIAA, is a private debt asset management firm providing flexible capital solutions to a wide range of businesses in Europe. Established in 2011, Arcmont has raised approximately €31 ($33) billion in assets to date from institutional investors globally and has committed over €31 ($33) billion across more than 410 transactions. With a highly experienced investment team, a strong investment track record and deep technical expertise, Arcmont offers creative and flexible capital solutions to European businesses, with the reliability of a partner that values long-term relationships. Headquartered in London, Arcmont’s presence spans Amsterdam, Frankfurt, Madrid, Milan, Munich, Paris, Stockholm and New York. it maintains a local origination network and builds and preserves close relationships with sponsors, borrowers and local intermediaries. To learn more about Arcmont, visit www.arcmont.com.

 

 

 

Media Contacts

Bianalisi

Francesca Alibrandi (Value Relations)

+39 335 8368826

f.alibrandi@vrelations.it

Antonella Martucci (Value Relations)

+39 340 6775463

a.martucci@vrelations.it

 

Carlyle

Andrew Kenny

Andrew.kenny@carlyle.com

+44 7816 176120

 

Marina Riva

M.Riva@barabino.it

Barabino

+39 347 2975426

 

 

Arcmont
Prosek
pro-arcmont@prosek.com

Categories: News

Tags:

Accel-KKR Credit Partners Provides Growth Financing to OneShield

AKKR Logo

Accel-KKR Credit Partners Provides Growth Financing to OneShield 

Menlo Park, CA & Marlborough, MA – Feb 27, 2025 – Accel-KKR Credit Partners today announced that it has provided growth financing to OneShield Software, a provider of core software systems to property & casualty  insurance carriers and managing general agents, including  startup insurers. Accel-KKR Credit Partners is a private credit fund managed by Accel-KKR, a leading global software-focused investment firm headquartered in Silicon Valley.  

“We are excited to announce our new partnership with Accel-KKR,” said Cameron Parker, CEO of OneShield. “We have spent the last few years investing in both of our platforms (OneShield Enterprise and OneShield Market Solutions), and we are leaning heavily into artificial intelligence to unlock additional value for our insurance customers. We have long been impressed with the depth and breadth of Accel-KKR’s software expertise, as well as their strategic insights on opportunities to further our upward momentum.” 

Founded in 1999, OneShield offers two innovative platforms for insurance carriers to provide a system of record and manage day-to-day operations. The software allows growing insurance companies to have continuity in technology across policy administration, billing and claims management. Additionally, OneShield offers enhanced capabilities including reinsurance, large schedule policy support and in-house agency management. With support for over 90 lines of businesses and deep experience in specialty lines, OneShield can help insurers quickly stand-up new insurance products to respond to evolving market needs.  

OneShield was acquired in September 2020 by a search fund led by brothers Cameron and Brandon Parker, with Pacific Lake Partners and Bain Capital Credit serving as anchor investors. Since that time, OneShield has grown with its existing insurance customers, and added numerous new logos to its roster. 

“Accel-KKR Credit Partners is the right partner for OneShield at this stage of our journey,” said Brandon Parker, President & COO of OneShield. “We were looking for a financing partner with a long-term perspective who understands the nuances of growing software companies. The team at Accel-KKR is very knowledgeable about our space and brought strategic capital solutions to the table. We look forward to the next chapter of growth with Accel-KKR as our financing partner.”  

“OneShield is led by a talented team who is bringing a fresh perspective to a mature market,” said Samantha Shows, Managing Director at Accel-KKR. “We have been impressed to see the evolution of the business since Cameron and Brandon’s stewardship, and we look forward to seeing the company continue its acceleration in the insurtech market.” 

About OneShield: 

OneShield provides business solutions for property and casualty insurers and MGAs of all sizes. The cloud-based and SaaS platforms include enterprise-level policy management, billing, claims, rating, relationship management, product configuration, business intelligence, and smart analytics. Designed specifically for personal, commercial, and specialty insurance, OneShield solutions support over 90 lines of business. OneShield’s clients, some of the world’s leading insurers, benefit from optimized workflows, pre-built content, seamless upgrades, collaborative implementations, and pricing models designed to lower the total cost of ownership. OneShield’s global footprint includes corporate headquarters in Marlborough, MA, with additional offices throughout India. Visit www.OneShield.com to learn more.  

About Accel-KKR: 

Accel-KKR is a technology-focused investment firm with over $21 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for topline and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs, and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, Chicago, London, and Mexico City. Visit accel-kkr.com to learn more. 

About Accel-KKR Credit Partners: 

Accel-KKR Credit Partners provides debt financing to leading software businesses. The fund structures non-dilutive investments for founder-owned businesses and flexible credit products for institutionally-owned businesses.  The debt capital is used to support acquisitions, dividends, shareholder buy-backs, and growth investment. Accel-KKR Credit Partners has completed over 80 investments and has deployed over $1 billion in capital. 

Categories: News

Tags: